Mekinist, marketed by GlaxoSmithKline, was approved May, 29, 2013, for the treatment of metastatic melanoma in adults with melanomas when the V600E or V600K mutations are present.
About 85% of patients with advanced melanomas carry the V600E mutation and about 10% carry the V600K mutation.
According to an efficacy trial of 322 patients, patient volunteers that received Mekinist delayed tumor growth by 3.3 months when compared topatients on chemotherapy. Patients who had previously been treated with Tafinlar, GSK's other skin cancer drug treatment, did not appear to benefit from Mekinist.
Generic name: trametinib
Product website: mekinist.com